Arrowhead Pharmaceuticals (ARWR) Reports Q4 Loss of $1.34
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $61.15 +2.72%
Financial Fact:
Change in value of derivatives: -113.36K
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Change in value of derivatives: -113.36K
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported Q4 EPS of ($1.34), versus ($1.60) reported last year. Revenue for the quarter came in at $158.33 thousand versus the consensus estimate of $382 thousand.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- SmartRent (SMRT) Reports In-Line Q3 EPS
- Datadog stock tumbles 19% despite earnings beat
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
